Log In
BCIQ
Print this Print this
 

KAN0439834 (formerly ROR-1 inhibitor)

  Manage Alerts
Collapse Summary General Information
Company Kancera AB
DescriptionROR1 inhibitor
Molecular Target Receptor tyrosine kinase-like orphan receptor 1 (ROR1)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationChronic lymphocytic leukemia (CLL)
Indication DetailsTreat chronic lymphocytic leukemia (CLL)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today